Basic information Safety Supplier Related

7,8,9,10-tetrahydroazepino(2,1-b)quinazolin-12(6H)-one

Basic information Safety Supplier Related

7,8,9,10-tetrahydroazepino(2,1-b)quinazolin-12(6H)-one Basic information

Product Name:
7,8,9,10-tetrahydroazepino(2,1-b)quinazolin-12(6H)-one
Synonyms:
  • 2,3-Pentanoquinazoline-4(3H)-one
  • 6,7,8,9,10,12-Hexahydroazepino[2,1-b]quinazoline-12-one
  • PD-139530
  • RLX
  • VASICINONE HCl (Deoxydihomo-'c'-)
  • 7,8,9,10-Tetrahydro-6H-azepino[2,1-b]quinazolin-12-one
  • Azepino[2,1-b]quinazolin-12(6H)-one, 7,8,9,10-tetrahydro-
CAS:
4425-23-4
MF:
C13H14N2O
MW:
214.26
Mol File:
4425-23-4.mol
More
Less

Safety Information

HS Code 
2933998090
Toxicity
LD50 oral in mouse: 1250mg/kg
More
Less

7,8,9,10-tetrahydroazepino(2,1-b)quinazolin-12(6H)-one Usage And Synthesis

Uses

RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

References

[1] The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment

7,8,9,10-tetrahydroazepino(2,1-b)quinazolin-12(6H)-oneSupplier

TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
TargetMol Chemicals Inc.
Tel
15002134094
Email
marketing@targetmol.cn
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
TargetMol Chemicals Inc.
Tel
+17819995354
Email
marketing@targetmol.com